Literature DB >> 29099733

Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.

Francois H Cornelis1, Jeremy C Durack, Michael J Morris, Howard I Scher, Stephen B Solomon.   

Abstract

PET/CT-guided interventions using specific radiotracers are promising for detecting avid lesions not well visualized with other imaging methods. A 72-year-old man who initially presented with prostate cancer Gleason 5 + 4 (prostate-specific antigen [PSA] = 7.9 ng/mL) underwent radical prostatectomy and node dissection. Three years after radiation, a rising PSA was observed over 6 months with PSA level reaching 1.08 ng/mL. He was evaluated with prostate-specific membrane antigen-based (PSMA) F-DCFPyL PET/CT, conventional CT, F-FDG PET/CT, and C-choline PET/CT. The PSMA F-DCFPyL PET/CT successfully targeted oligometastatic prostate cancer, whereas the other imaging studies were not correct in assessing disease extent.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29099733      PMCID： PMC5736003          DOI： 10.1097/RLU.0000000000001846

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  11 in total

1.  SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0.

Authors:  George Segall; Dominique Delbeke; Michael G Stabin; Einat Even-Sapir; Joanna Fair; Rebecca Sajdak; Gary T Smith
Journal:  J Nucl Med       Date:  2010-11       Impact factor: 10.057

Review 2.  Interventional Molecular Imaging.

Authors:  Stephen B Solomon; Francois Cornelis
Journal:  J Nucl Med       Date:  2016-02-11       Impact factor: 10.057

3.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.

Authors:  Neeta Pandit-Taskar; Joseph A O'Donoghue; Jeremy C Durack; Serge K Lyashchenko; Sarah M Cheal; Volkan Beylergil; Robert A Lefkowitz; Jorge A Carrasquillo; Danny F Martinez; Alex Mak Fung; Stephen B Solomon; Mithat Gönen; Glenn Heller; Massimo Loda; David M Nanus; Scott T Tagawa; Jarett L Feldman; Joseph R Osborne; Jason S Lewis; Victor E Reuter; Wolfgang A Weber; Neil H Bander; Howard I Scher; Steven M Larson; Michael J Morris
Journal:  Clin Cancer Res       Date:  2015-07-14       Impact factor: 12.531

Review 4.  The Role of PET Imaging Before, During, and After Percutaneous Hepatic and Pulmonary Tumor Ablation.

Authors:  Eric D McLoney; Ari J Isaacson; Patrick Keating
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

5.  PET/CT-guided percutaneous biopsy of abdominal masses: initial experience.

Authors:  Servet Tatli; Victor H Gerbaudo; Christina M Feeley; Paul B Shyn; Kemal Tuncali; Stuart G Silverman
Journal:  J Vasc Interv Radiol       Date:  2011-03-02       Impact factor: 3.464

6.  89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Authors:  Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis
Journal:  J Nucl Med       Date:  2010-07-21       Impact factor: 10.057

7.  PET-CT-guided interventions in the management of FDG-positive lesions in patients suffering from solid malignancies: initial experiences.

Authors:  Bernd Klaeser; Michel D Mueller; Ralph A Schmid; Carlos Guevara; Thomas Krause; Jakub Wiskirchen
Journal:  Eur Radiol       Date:  2009-02-24       Impact factor: 5.315

Review 8.  The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?

Authors:  R Schiavina; F Ceci; M Borghesi; E Brunocilla; V Vagnoni; M Gacci; P Castellucci; C Nanni; G Martorana; S Fanti
Journal:  Curr Radiopharm       Date:  2013-06-06

9.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.

Authors:  D G Bostwick; A Pacelli; M Blute; P Roche; G P Murphy
Journal:  Cancer       Date:  1998-06-01       Impact factor: 6.860

10.  Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Authors:  F Cornelis; M Silk; H Schoder; H Takaki; J C Durack; J P Erinjeri; C T Sofocleous; R H Siegelbaum; M Maybody; S B Solomon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-09       Impact factor: 9.236
View more
  3 in total

Review 1.  Radiotheranostics: a roadmap for future development.

Authors:  Ken Herrmann; Markus Schwaiger; Jason S Lewis; Stephen B Solomon; Barbara J McNeil; Michael Baumann; Sanjiv S Gambhir; Hedvig Hricak; Ralph Weissleder
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

2.  Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.

Authors:  Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu
Journal:  World J Urol       Date:  2022-10-02       Impact factor: 3.661

3.  A Pilot Study of 18F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions.

Authors:  Yachao Liu; Hongkai Yu; Jiajin Liu; Xiaojun Zhang; Mu Lin; Holger Schmidt; Jiangping Gao; Baixuan Xu
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.